PT  - JOURNAL ARTICLE
AU  - Aiwara, Stanley
AU  - Kevau, Isi H.
AU  - Linge, David
AU  - Aglua, Izzard
TI  - Clinical predictors of treatment outcome in adult Tuberculous Meningitis patients at the Kundiawa General Hospital
AID  - 10.1101/2022.09.03.22279565
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.03.22279565
4099  - http://medrxiv.org/content/early/2022/09/04/2022.09.03.22279565.short
4100  - http://medrxiv.org/content/early/2022/09/04/2022.09.03.22279565.full
AB  - Background Tuberculous meningitis is the most severe form of extrapulmonary TB and accounted for 5 % of 10 million TB cases globally in the WHO 2018 report, with mortality as high as 19.35% in children and 30% in adults. Clinicians in resource-poor settings are often challenged with limited diagnostic and therapeutic options for optimal patient care, and often rely on clinical parameters for diagnosis, treatment, monitoring and outcome prediction.Aim This study was done to identify potential clinical predictors of i) length of in-hospital stay, and ii) death or discharge at 28 days, amongst Melanesian adults with TB meningitis at the Kundiawa General Hospital in Simbu Province of Papua New Guinea.Method A retrospective observational study was conducted on 65 Melanesian adults with TB meningitis at the Kundiawa General Hospital in Simbu province between 2015 and 2019.Result High case fatality (48%) and mortality rates (2.22 per 100,000 per year) for TB Meningitis in this study. Even higher case fatality of 90.9% with HIV co-infection. Parameters associated with higher 28-day mortality included admission GCS (P=0.039, 95% CI), HIV-TBM co-infection (P=0.049, 95% CI), positive fluid balance 24 hours after admission (P=0.061, 95% CI) and male gender (P=0.057, 95% CI).Conclusion Study showed high case fatality (48%) and mortality rates (2.22 per 100,000 per year) for adult TB Meningitis, with even higher case fatality (90.9%) for HIV-TB co-infection. Admission GCS, positive fluid balance 24 hours after admission, HIV-TB co-infection and male gender were associated with higher 28-day mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical consideration and approval was granted by the interim Institutional Review Committee of the SiPHA-Clinical Research Center.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsTBMTuberculous MeningitisTBTuberculosisWHOWorld Health OrganizationGCSGlasgow Coma ScaleCSFCerebrospinal FluidPCRPolymerase Chain ReactionCIConfidence IntervalAFBAcid Fast BacilliNGTNasogastric TubeSiPHASimbu Provincial Health Authority.